期刊文献+

他汀类药物的临床应用及不良反应研究进展 被引量:51

Clinical application of statins and their major adverse effects
下载PDF
导出
摘要 他汀类药物是一线降脂药物,也是心血管疾病的预防药物,临床应用和研究范围正不断扩大。他汀类药物临床应用研究主要关注心血管疾病一级预防、充血性心力衰竭的治疗、对糖尿病发病的影响等。近年来,他汀类药物的不良反应,特别是肝毒性和肌毒性也愈发引起人们的关注。肝毒性主要表现为转氨酶升高,严重者引起肝功能衰竭;肌毒性主要表现为肌痛、抽搐等,严重者会引起横纹肌溶解症。临床上主要采用监测血清丙氨酸转氨酶或磷酸肌酸激酶,结合临床表现并及时减量或停药的方法来防止严重不良反应的发生,一些新的治疗方案还在研究中。深入研究他汀类药物不良反应的发生机制,开发有效的辅助治疗方法或复方药物有助于该类药物的安全应用。 Statins, the first-line lipid-lowering agents, are also used as the secondary prevention drugs for cardiovascular disease. The excellent curative effects on hyperlipidemia-associated cardiovascular diseases have expanded the scope of their clinical application. Currently, the research direction on the clinical applications of statins involves primary prevention of cardiovascular disease, congestive heart failure treatment, the impact on the incidence of diabetes, etc. However, the side effects of statins, especially liver and muscle toxicity, have increasingly aroused people's attention. The main symptom of hepatotoxicity is the elevated level of blood se- rum aminotransferase, and in very few severe cases it can lead to liver failure. The main symptoms of myotoxicity are myalgia, muscle weakness, or even rhabdomyolysis. In clinics, severe adverse effects are prevented by decreasing the dosage or terminating statin therapy. Further study on the mechanisms of adverse effects of statins and development effective adjuvant therapies or combination prescrip- tions would be beneficial for using statins safely and effectively.
作者 张冰 王莉莉
出处 《国际药学研究杂志》 CAS CSCD 2013年第5期560-564,572,共6页 Journal of International Pharmaceutical Research
关键词 他汀类 临床应用 不良反应 肝毒性 肌毒性 statins clinical application adrerse reaction hepatotoxicity myotoxicity
  • 相关文献

参考文献1

二级参考文献12

  • 1[1]de Denus S,Spinler SA,Miller K,Peterson AM.Statins and liver toxicity:a meta-analysis.Pharmacotherapy 2004; 24:584-591
  • 2[2]Rosenson RS.Rosuvastatin:a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.Expert Rev Cardiovasc Ther 2003; 1:495-505
  • 3[3]Naranjo CA,Busto U,Sellers EM,Sandor P,Ruiz I,Roberts EA,Janecek E,Domecq C,Greenblatt DJ.A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther 1981; 30:239-245
  • 4[4]Ramos Ramos JC,Sanz Moreno J,Calvo Carrasco L,Garcia Diaz Jde D.Clopidogrel-induced hepatotoxicity.Med Clin (Barc) 2003; 120:156-157
  • 5[5]Duran Quintana JA,Jimenez Saenz M,Montero AR,Gutierrez MH.Clopidogrel probably induced hepatic toxicity.Med Clin (Barc) 2002; 119:37
  • 6[6]Willens HJ.Clopidogrel-induced mixed hepatocellular and cholestatic liver injury.Am J Ther 2000; 7:317-318
  • 7[7]Yeung E,Wong FS,Wanless IR,Shiota K,Guindi M,Joshi S,Gardiner G.Ramipril-associated hepatotoxicity.Arch Pathol Lab Med 2003; 127:1493-1497
  • 8[8]Fry SW,Seeff LB.Hepatotoxicity of analgesics and antiinflammatory agents.Gastroenterol Clin North Am 1995; 24:875-905
  • 9[9]White CM.A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.J Clin Pharmacol 2002; 42:963-970
  • 10[10]Tornio A,Pasanen MK,Laitila J,Neuvonen PJ,Backman JT.Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.Basic Clin Pharmacol Toxicol 2005; 97:104-108

共引文献7

同被引文献446

引证文献51

二级引证文献170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部